New trials, publications, preprints and grants on this target, month by month.
Trial
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma
1 Apr 2028· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Matrix‑stiffness‑triggered mechanotransduction fuels hepatocellular carcinoma proliferation through Hippo‑orchestrated ANKRD1‑PRMT5 complex‑driven arginine methylome remodeling.
24 Oct 2026· Military Medical Research· PUBMED
Publication
Role of PRMT5 in regulating ferritinophagy during Mycobacterium tuberculosis infection.
22 Sept 2026· PLoS pathogens· PUBMED
Publication
Targeting PRMT5 with indole-based arylsulfonylhydrazides: a novel epigenetic strategy for the treatment of acute and chronic leukemia.
15 Sept 2026· American journal of cancer research· PUBMED
Publication
Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8⁺ T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy.
14 Sept 2026· Oncogene· PUBMED
Publication
Cryo-EM structure-based discovery of etravirine as a specific inhibitor of PRMT5/pICln protein-protein interaction for prostate cancer treatment.
8 Sept 2026· Journal of enzyme inhibition and medicinal chemistry· PUBMED
Publication
PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer.
2 Sept 2026· Molecular cancer therapeutics· PUBMED
Publication
Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.
1 Sept 2026· Cancer research communications· PUBMED
Publication
MTAP loss in non-small-cell lung Cancer and beyond: Therapeutic targeting of the MAT2A-PRMT5 axis.
29 Aug 2026· Cancer treatment reviews· PUBMED
Publication
PRDX1 drives colorectal cancer progression and immune microenvironment remodeling by facilitating PRMT5 nuclear translocation to activate Wnt/β-catenin signaling.
27 Aug 2026· International journal of biological macromolecules· PUBMED
Trial
BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion
21 Aug 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Publication
Acquired Resistance to the PRMT5 Inhibitor Confers Collateral Sensitivity to MEK Inhibition in MTAP-Null Non-Small Cell Lung Cancer.
17 Aug 2026· Biomolecules· PUBMED
Publication
Systemic administration of the PRMT5 inhibitor GSK3326595 does not induce overt cardiotoxicity in the murine heart.
15 Aug 2026· Journal of molecular and cellular cardiology plus· PUBMED
Publication
Flavokawain A inhibits high glucose-induced malignant progression of lung cancer cells by suppressing PRMT5-mediated PTEN neddylation and nuclear translocation.
14 Aug 2026· Oncology letters· PUBMED
Publication
PPM1B suppresses cervical carcinoma invasion by dephosphorylating MYPT1 at Thr853 and inactivating the PRMT5 epigenetic axis.
8 Aug 2026· European journal of cell biology· PUBMED
Publication
Targeting PRMT5 to reshape the immune microenvironment and reverse Trop2 ADC resistance in triple-negative breast cancer.
4 Aug 2026· Cellular oncology (Dordrecht, Netherlands)· PUBMED
Publication
Discovery of novel cereblon-recruiting PRMT5 degraders with in vivo efficacy against triple-negative breast cancer.
1 Aug 2026· European journal of medicinal chemistry· PUBMED
Trial
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
27 Jul 2026· PHASE2 · RECRUITING· CTGOV
Publication
PRMT5 promotes psoriatic inflammation through mediating dimethylation of p65 in keratinocytes.
10 Jul 2026· Molecular medicine (Cambridge, Mass.)· PUBMED
Publication
PRMT5 as a Key Driver of Stemness and Metastatic Potential in Triple-Negative Breast Cancer.
20 Jun 2026· Biomolecules· PUBMED
Publication
PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?
19 Jun 2026· Annals of oncology : official journal of the European Society for Medical Oncology· PUBMED
Publication
PCK2-Mediated PQBP1 Lactylation Promotes Asthmatic Inflammation through PRMT5 Inhibition.
19 Jun 2026· Research (Washington, D.C.)· PUBMED
Publication
PRMT5-mediated methylation of LKB1 controls PD-L1 expression in NSCLC.
10 Jun 2026· Biomedical journal· PUBMED
Publication
PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.
5 Jun 2026· Journal of neuro-oncology· PUBMED
Publication
PRMT5 is a prognostic-related biomarker associated with the tumor immune microenvironment in lung adenocarcinoma.
5 Jun 2026· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publication
LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer.
2 Jun 2026· Cell reports· PUBMED
Publication
Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma.
21 May 2026· European journal of medicinal chemistry· PUBMED
Publication
Arginine methylation of human DNA topoisomerase I by PRMT5 facilitates DNA relaxation.
20 May 2026· Nucleic acids research· PUBMED
Publication
The Discovery of TNG456: A Highly Potent, Selective, Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.
18 May 2026· Journal of medicinal chemistry· PUBMED
Publication
Inhibition of PRMT5 sensitizes B-cell non-Hodgkin lymphoma cells to both intrinsic and extrinsic apoptotic cell death.
16 May 2026· Blood neoplasia· PUBMED